OBJECTIVES: Cost-Utility analysis of Spinal Cord Stimulation Rechargeable (SCS-RC) vs. reoperation in the treatment of Failed Back Surgery Syndrome (FBSS) in Colombia. METHODS: Through the adaptation of an economic model developed by Sigmatic Ltd t/a Abacus International for UK NICE submission, and previous data transferability analysis, a cost utility analysis was done comparing SCS-RC  vs. Reoperation in patients with FBSS in Colombia. One short analytical decision tree and one long term Markov model were considered for model conceptualization of the health problem and treatment impact. The effectiveness and utility data was primarily based on data from the PROCESS trial combined with Colombian costing data. A 15 years horizon, a third party payer perspective and 3% discount rate for utilities and costs were assumed.  The Health states considered, at annual cycles, were optimal pain relief, optimal pain relief with complications, sub-optimal pain relief, and sub-optimal pain relief with complications. Optimal pain relief occurs with a pain threshold of 50%. Incremental analysis along with univariate and probabilistic sensitivity analysis was done. RESULTS: SCS-RC had an incremental costs of US$11.223 and 1,09 incremental QALYs, with an ICER of US$10.293 which is far lower than the US$24.300 GDP Percapita recommended by the WHO as threshold for development countries and a 62,2% probability of been cost-effective, when probabilistic analysis was ran. CONCLUSIONS: SCS-RC showed a 62,2% probability of been cost-effective when compared to Reoperation in patients with FBSS in Colombia.